Cutting Calories Suppresses a Hidden Inflammation Driver Tied to Aging, Study Finds

Chronic, low-grade inflammation that accumulates as we age, a process researchers call inflammaging, is increasingly linked to conditions ranging from metabolic disease to cognitive decline. Most people trying to manage their gut health, energy, or immune function will have heard that diet matters, but the mechanisms connecting what we eat to how our immune system ages have remained fuzzy. A study published in Nature Aging now pinpoints a specific protein, C3a, as a measurable driver of this process, and shows that a sustained but modest cut in calories can suppress it, independently of weight loss.

Key takeaways:

• C3a, a fragment of the complement immune protein C3, rises with age and drives inflammatory signaling in visceral fat.
• Just 14% calorie restriction for two years lowered C3a and multiple other complement proteins in healthy middle-aged humans.
• The primary source of age-related C3a appears to be a specific population of macrophages (immune cells) inside visceral fat tissue.
• FDA-approved C3 inhibitors already exist, but clinical trials are still needed to establish safe dosing for long-term anti-aging use.

Calorie Restriction Suppresses C3a and Broader Complement Activation in Humans

Two years of 14% calorie restriction significantly reduced plasma levels of multiple complement proteins in healthy middle-aged adults, with C3a being the only complement component reduced independently of BMI in both sexes. The CALERIE-II clinical trial, which enrolled 42 participants and used an unbiased plasma proteomics platform called the SomaScan 7K assay to measure roughly 7,000 proteins, found that CR also lowered C1s, C1r, CFB (complement factor B), CFD (complement factor D), C3adesArg (a stable breakdown product of C3a), C5, and C9. The breadth of that suppression suggests CR dampens the entire complement cascade, not just one branch of it. CR also reduced leptin and FABP4 (fatty acid binding protein 4, a marker of metabolic inflammation) while raising adiponectin, a protein associated with insulin sensitivity and metabolic health.

Beyond individual proteins, CR slowed what the researchers call the proteomic aging clock specifically in adipose (fat) tissue, using an algorithm called 'organage' to estimate how much older or younger specific organs appear based on their protein profiles. The finding positions fat tissue as a key target organ for dietary interventions, not merely a passive energy store.

Why Visceral Fat Specifically Drives Age-Related Inflammation

Visceral adipose tissue (VAT), the fat that accumulates around internal organs rather than under the skin, showed a unique age-associated increase in C3 cleavage (the enzymatic process that generates C3a from C3) in both male and female mice. The same increase was not seen in subcutaneous fat (SAT), brown adipose tissue (BAT), liver, spleen, or kidney. For people managing conditions like metabolic syndrome, type 2 diabetes, or non-alcoholic fatty liver disease, where excess visceral fat is already a known risk factor, this is worth noting: the study suggests VAT may be doing more than storing energy; it may be actively broadcasting inflammatory signals through the complement system as it ages.

Single-cell RNA sequencing of VAT immune cells identified a specific macrophage population called age-associated macrophages (AAMs) as the primary cellular source of age-related C3. These AAMs were not characterized by the usual markers of cellular senescence (the zombie-cell state often blamed for inflammaging), which suggests a distinct and previously underappreciated mechanism. C3 and its receptor C3AR1 were both enriched in adipose tissue macrophages, setting up an autocrine loop: macrophages produce C3a, sense it through their own receptors, and amplify inflammation as a result.

How the ERK Signaling Pathway Connects C3a to Inflammatory Cytokines

In bone marrow-derived macrophages treated with recombinant C3a, the researchers traced the downstream inflammatory signal to ERK (extracellular signal-regulated kinase), a well-characterized intracellular signaling protein. C3a drove production of IL-1beta and IL-6, two cytokines central to chronic inflammation, through ERK activation. STAT3, another signaling protein activated by C3a, was not required for this cytokine response. Separately, autocrine C3a-C3AR1 signaling in adipose tissue macrophages activated both ERK and STAT3. This mechanistic detail matters because ERK is a druggable target with an existing pharmacology, and understanding exactly which branch of signaling drives harmful outcomes versus adaptive ones will shape how future interventions are designed.

To test whether blocking C3a in living animals changes the inflammatory environment in fat, the team delivered a C3a-specific neutralizing antibody directly into the VAT of aged mice. This reduced frequencies of total adipose tissue macrophages, Ly6C+ monocytes, and regulatory T cells, while elevating M2-like macrophages, which are associated with tissue repair rather than inflammation. The intervention did not, however, conclusively lower serum complement levels, and the durability of the antibody experiments was limited, leaving the causal link between C3a inhibition and healthspan extension still to be firmly established.

What This Could Mean If You Are Managing an Inflammatory Condition

For a self-directed reader already living with an inflammatory or metabolic condition, several threads here are worth flagging, with the caveat that this research is emerging and not yet practice-changing. First, the CR effect was achieved at 14% calorie reduction, not the severe restriction often studied in animal models. That is a meaningful but achievable reduction for some people, though the study enrolled healthy middle-aged adults and did not test people with existing chronic disease. Second, the adipose-specific finding suggests that interventions targeting visceral fat, whether through diet, exercise, or pharmacology, may have immune effects beyond the metabolic ones already well-established.

Two existing prolongevity interventions were also linked to reduced C3 cleavage in VAT: FGF21 overexpression and PLA2G7 knockout. These are not yet clinical tools, but they corroborate the C3a pathway as a genuine target rather than an artifact. More immediately relevant: pegcetacoplan, an FDA-approved C3 inhibitor currently prescribed for age-related macular degeneration and certain blood disorders, already exists. The authors note that careful clinical trials are needed to determine appropriate dosing for long-term anti-aging use, and that is the honest framing: the drug exists, but its application here remains experimental.

Limitations and Open Questions About C3a in Aging

Several caveats are worth stating plainly. The human proteomics data came from 42 participants, a relatively small cohort; a larger sample could surface subtler patterns and confounders. The mechanistic mouse work establishes plausibility but not proof that C3a inhibition extends healthspan in humans. The neutralizing antibody experiments in mice were limited in duration. And as research into personalized nutrition consistently shows, inter-individual variability in how diet affects metabolism and immunity is substantial, meaning a population-average effect may mask wide individual differences.

Disentangling the effects of calorie restriction from those of weight loss will also require future studies with careful design, since CR and BMI reduction tend to co-occur. The authors acknowledge that tissue-specific effects of CR, uncoupled from weight loss, need dedicated investigation. How macrophage-specific C3 production reshapes the broader adipose tissue environment during aging is another open question the team flags for follow-up with genetically modified mouse models. For anyone interested in the methodological standards required to move from correlation to causation in diet-immune research, this study represents a strong mechanistic step forward while being transparent about where the causal chain remains incomplete.

Common Questions

Does this mean calorie restriction is proven to slow aging? No. This study shows CR at 14% over two years suppresses specific inflammatory proteins, including C3a, in healthy middle-aged humans. It does not establish that this extends lifespan or prevents specific diseases; that kind of evidence would require much longer trials with clinical endpoints.

Is visceral fat the only fat type that matters here? Based on this study, the age-related increase in C3 cleavage was specific to visceral adipose tissue in mice, not subcutaneous or brown fat. Whether the same tissue-specificity holds in humans at a mechanistic level is not yet confirmed.

Could someone take a C3 inhibitor like pegcetacoplan to slow aging now? The authors explicitly call for careful clinical trials to establish safe long-term dosing before this use case is pursued. Pegcetacoplan is currently approved for specific blood and eye conditions, not for anti-aging indications.

References

1. Manish Mishra, Hee-Hoon Kim, Yun-Hee Youm, et al. (2026). Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging. Nature Aging. https://doi.org/10.1038/s43587-026-01107-0
2. Katie Wright (2025). The Future of Microbiome-Based Therapeutics. European Medical Journal. https://doi.org/10.33590/emj/ctgy2726
3. Meghna Verma, Raquel Hontecillas, Nuria Tubau-Juni, Vida Abedi, Josep Bassaganya-Riera (2018). Challenges in Personalized Nutrition and Health. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2018.00117
4. Yangwenshan Ou, Clara Belzer, Hauke Smidt, Carolina de Weerth (2024). Methodological recommendations for human microbiota-gut-brain axis research. Microbiome Research Reports. https://doi.org/10.20517/mrr.2023.33